NICE Approves Ruxolitinib Cream for Treating Vi...

By HEOR Staff Writer

February 25, 2026

NICE Backs Ruxolitinib Cream Vitiligo Treatment Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), w...
SAHPRA GMP Compliance: Addressing Allegations Against Adcock Ingram’s C...
Economic Impact of Industry Clinical Trials in Europe
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
EMA Executive Director Recruitment: Leading the Future of Medicines Regulation
Biopharma Ecosystem Competitiveness: Post-COVID Challenges and Opportunities
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Enhancing Safety and Performance: The Role of EU Medical Device Panels
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation